Acerus Pharmaceuticals (OTCMKTS:TRLPF – Get Rating) and Kiora Pharmaceuticals (NASDAQ:KPRX – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk. Risk and Volatility Acerus Pharmaceuticals has a beta of […]
Kiora Pharmaceuticals (NASDAQ:KPRX – Get Rating) had its price objective dropped by research analysts at Maxim Group to $1.00 in a research note issued on Thursday, Stock Target Advisor reports. Maxim Group’s target price points to a potential upside of 149.94% from the company’s previous close. Separately, HC Wainwright dropped their price target on Kiora […]
Kiora Pharmaceuticals (NASDAQ:KPRX – Get Rating) is one of 939 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Kiora Pharmaceuticals to similar companies based on the strength of its earnings, profitability, institutional ownership, dividends, risk, analyst recommendations and valuation. Profitability This table compares […]
Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX – Get Rating) saw a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 209,200 shares, a growth of 60.9% from the April 15th total of 130,000 shares. Currently, 1.8% of the company’s shares are sold short. Based on an average […]